infection and excessive immune-mediated inflammatory process (2). Recently, increased concentrations of eosinophil-derived granule proteins, such as eosinophil cationic protein (ECP), eosinophil protein X (EPX), and eosinophil peroxidase (EPO), have been detected in both sputum and serum samples of patients with CF (3, 4). In addition, serum levels of eosinophil granule proteins are significantly related to pulmonary function and disease severity in CF (4, 5). Due to the cytotoxic potential of these proteins, it has been assumed that the activated eosinophil, in addition to the neutrophil granulocyte, also participates in pulmonary tissue damage (3). However, in addition to bacterial infection, colonization with fungi, predominately Aspergillus fumigatus, is frequently observed in CF (6), commonly resulting in IgE-mediated sensitization to this fungus. Moreover, it has been demonstrated that Aspergillus sensitization in the presence of increased total serum IgE levels is associated with lower pulmonary function values in children with CF (7), emphasizing the role of IgE-mediated sensitization in CF. In contrast to bronchial asthma (8), eosinophil activity is not enhanced in atopic compared with nonatopic patients with CF, as shown by the lack of any relationship between the levels of ECP, EPX, or EPO and the atopic status of patients with CF (4). Therefore, other mechanisms of eosinophil activation in CF compared with bronchial asthma have been suggested (9). Despite this, however, it appears unlikely that IgE-mediated events do not contribute in CF to enhanced eosinophil degranulation as measured by ECP, EPX, and EPO (4).
Since there is some evidence that eosinophil-granule proteins are released differentially in vitro (10), we investigated whether serum and sputum levels of major basic protein (MBP) are influenced by additional IgE-mediated sensitization in patients with CF. To have a homogeneous cohort, all of the patients studied were in stable clinical condition, and all of them were chronically infected/ colonized by Pseudomonas aeruginosa.
Material and methods

Patients and controls
Forty patients with CF (age: 12.5u3.47 years; 22 girls and 18 boys) were recruited. The diagnosis was confirmed by repeated positive sweat test results and typical course of disease. All of them were in a stable clinical condition, meaning that none of the patients suffered from acute pulmonary exacerbation as defined previously (4). Disease severity was determined by means of the Shwachman± Kulczycki score (11) , which in our setting (12) was limited to the maximum of 75 points (i.e., excluding radiography) (Table 1) . Chronic infection/colonization by P. aeruginosa was proved by repeated sputum cultures in all patients.
In addition, in 14 patients with CF, the diagnosis of atopy was based on increased total serum IgE proteins (above the age-related normal values) ( Table 1) 
Sputum preparation
Sputum samples were diluted immediately with phosphatebuffered saline (PBS), pH 7.4, in order to avoid cell damage, and were vortex mixed for 30 s, according to a previously published protocol (3, 9). The mixture was centrifuged, and the supernatant was immediately frozen at ±208C until analysis.
An aliquot of diluted sputum from each patient was used for cell differential counts and was stained with MayGru È nwald-Giemsa. It has been previously shown by trypan blue exclusion that the viability of cells in samples was above 65%. Moreover, the percentage of squamous cells was less than 10%, indicating that no notable salivary contamination was present (13). 
Pulmonary function test
Pulmonary function tests were performed by means of a whole-body plethysmograph (Masterlab, Jaeger, Germany). (18) .
Blood gas analysis
Arterial P O2 and P CO2 values were determined in arterialized ear-lobe capillary blood (Blood Gas Analyzer 1306 pH;
Instrumentation Laboratory, USA).
Statistical analysis
Results are presented as meanuSD unless mentioned otherwise. The coefficient of correlation was calculated by the Spearman ranks correlation procedure. The Mann± Whitney U test was used for differences between the groups. Probabilities of less than 5% were considered significant.
Results
Clinical characteristics
Detailed demographic data of the patients are summarized in Table 1 . Subdivision into atopic (n=14) and nonatopic (n=26) subjects demonstrated for total serum IgE levels a significant difference (381u261.4 kU/l [range 142±884
kU/l) vs 36u16.7 kU/l [range 6±60 kU/l); P,0.0001). No significant differences for pulmonary function variables or other clinical parameters, such as Shwachman±Kulczycki score and blood gas analysis, were detected.
Eosinophil counts and eosinophil granule proteins in serum
Eosinophil counts were low in most of the patients with CF (234u117.3 eosinophils/ml; range 80±520 eosinophils/ml). In addition, no significant differences were found between atopic and nonatopic patients (210u114.6 vs 247u118.9 eosinophils/ml). In contrast to blood eosinophil counts, increased ECP levels (29.7u21.01 mg/l; range: 6.4±85 mg/l), EPX levels (53.7u31.27 mg/l; range: 15.4±145.2 mg/l), and MBP levels (984.6u370.55 mg/l; range: 412.2±1880.3 mg/l)
were measured. In serum, MBP levels were significantly correlated with the levels of ECP (r=0.348, P,0.03) and EPX (r=0.321, P,0.05).
Moreover, serum MBP (Fig. 1 8.0±146.9 mg/l) were detected. However, sputum concentrations of MBP were closely related to those of ECP (r=0.721, P,0.0001) and EPX (r=0.567, P,0.0004).
No differences in eosinophil granule protein levels in sputum between atopic (ECP 2.78u0.85 mg/l and EPX 8.52u1.16 mg/l) and nonatopic patients (ECP 2.65u0.88 mg/l and EPX 7.63u1.61 mg/l) with CF were observed ( Fig. 1 shows the results for MBP). In addition, in atopic subjects, no influence on eosinophil activity by A. fumigatus sensitization was seen (Table 2) .
Discussion
The present study has demonstrated high concentrations of ECP, EPX, and MBP in serum and of ECP and EPX in sputum derived from patients with CF. This finding supports previous results in patients with CF showing increased serum and sputum ECP levels (3, 4). Moreover, we have found that serum MBP levels, but not those for ECP and EPX, were significantly elevated in CF patients with sensitization to inhalant allergens, compared with nonsensitized subjects. This was not seen for eosinophil counts in peripheral blood.
The lack of blood and sputum eosinophilia does not exclude the participation of the eosinophil in the inflammatory process, as recently demonstrated, for example, in wheezing infants (19) . The dissociation between eosinophil Results are presented as individual values and as meanuSD. Significant correlation between serum MBP and total serum IgE (r=0.717, P,0.0001) was found. Such relationship was not observed for other eosinophil granule proteins in serum or for eosinophil-derived proteins in sputum. In addition, MBP in either serum or sputum samples was not related to levels of specific IgE antibodies. number in peripheral blood ± which was within the normal range in most of the patients (3) ± and the serum concentrations of eosinophil granule proteins in CF might be explained by the fact that blood eosinophils actively release their granule proteins during clot formation in vitro.
The enhanced degranulation may reflect the fact that eosinophils are primed by eosinophil-active factors.
Indeed, we have previously demonstrated that isolated blood eosinophils from patients with CF have an increased propensity to release ECP after stimulation with serumtreated Sephadex G-15 particles, indicating that the eosinophil must be primed (12) . One putative principle involved in the priming of eosinophils is interleukin (IL)-5, as has been demonstrated in vitro and in vivo for bronchial asthma (20) .
In CF, however, studies on cytokines in sputum samples have shown that in most of the patients IL-5 could not be detected (9). Therefore, the other priming factors involved could be cytokines such as IL-3 and IL-8, since both were found to be increased in sputum samples from patients with CF, and they were markedly correlated with eosinophil activity (9). The lack of sputum eosinophilia in most of the patients might be due to the fact that after total degranulation the eosinophil cannot be identified by the usual staining procedure. However, the participation of activated eosinophils in the inflammatory process in the CF lung appears to be substantiated by the presence of very high sputum concentrations of ECP and EPX ± higher than those needed for tissue injury in vitro ± as shown by our group and others (3, 9, 21).
Surprisingly, the levels of MBP in sputum samples from patients with CF were low despite increased ECP and EPX values. It has been shown that patients with bronchial asthma had similar sputum ECP levels to those of subjects with CF (9, 22). In addition, sputum MBP concentrations higher than 100 mg/l have been described in bronchial asthma (23), whereas 32 of our patients with CF had values less than 100 mg/l. Moreover, these sputum concentrations of MPB were substantially lower than those in serum (range 412.2±1.880.3 mg/l; for comparison, in asthmatics, a mean concentration of 384 mg/l has been described [24] ). The reason for this phenomenon might be either that MBP is degraded by the presence of proteolytic enzymes in the sputum of patients with CF, or that eosinophil granule proteins are released differentially in serum and sputum (10).
Since the recovery rate for ECP and EPX is is 85±107% in sputum samples derived from patients with CF, it appears unlikely that among these proteins only MBP should be degraded. Nonetheless, there is some evidence from this study that eosinophil proteins are released differentially from the granules. This phenomenon is probably due to the fact that MBP is localized to the crystalline core of the eosinophil-specific granules whereas ECP, EPX, and eosinophil peroxidase are present within the amorphous granule matrix (25) . A difference in solubilization rates between matrix and core may possibly account for the differential release of these proteins.
It has been demonstrated that sensitization to inhalant allergens, especially A. fumigatus, is associated with lower pulmonary function values in patients with CF (7), and the observation may be due to the presence of MBP, which is detected in higher serum concentrations in atopic than in nonatopic patients with CF, and in Aspergillus-sensitized than in nonsensitized subjects. Thus, our findings of increased serum MBP levels suggest that inhalant allergy contributes to enhanced eosinophil activity in CF, as observed in childhood asthma (8).
In conclusion, in serum samples obtained from patients with CF, high levels of MBP can be measured. In addition, blood eosinophils of allergic subjects with CF released higher amounts of MBP than those of nonallergic subjects. 
